Prenen Hans, Gil Thierry, Awada Ahmad
Department of General Medical Oncology, University Hospital Gasthuisberg, Catholic University Leuven, Herestraat 49, 3000 Leuven, Belgium.
Crit Rev Oncol Hematol. 2009 Jan;69(1):56-63. doi: 10.1016/j.critrevonc.2008.07.007. Epub 2008 Aug 26.
Metastatic renal cell cancer is associated with a poor prognosis and is very resistant to conventional cytotoxic chemotherapy. Progress in the understanding of molecular biology and pathogenesis of renal cell cancer has been translated into the development of new therapeutic strategies. The recent approval of sunitinib, sorafenib, temsirolimus and bevacizumab in combination with IFN-alpha has revolutionized the management of renal cell carcinoma. In this review, we describe the status of current treatment strategies for metastatic renal cell cancer and we focus on the new compounds including targeted therapy such as new anti-angiogenic and mTOR inhibitors.
转移性肾细胞癌预后较差，对传统细胞毒性化疗具有很强的耐药性。对肾细胞癌分子生物学和发病机制认识的进展已转化为新治疗策略的开发。舒尼替尼、索拉非尼、替西罗莫司和贝伐单抗联合α干扰素最近获得批准，彻底改变了肾细胞癌的治疗方式。在本综述中，我们描述了转移性肾细胞癌当前治疗策略的现状，并重点关注新的化合物，包括新的抗血管生成和mTOR抑制剂等靶向治疗。
